Oravax, Inc.

Oravax-Merieux Co.

William D Thomas

Thomas P Monath

James Scott Moncrief

David Maxwell Lyerly

Harold Kleanthous

Farshad Guirakhoo

Samuel K Ackerman

Richard A Weltzin

Cynthia K Lee

Zhenxi Zhang

Wende Lei

Gopalan Soman

Hitesh Bhagat

Jacques Pappo

Francisco Javier Torres-Lopez

Ilene Sussman

Thomas Ermak

The invention features methods and compositions for inducing protective and/or therapeutic immune responses to an antigen in a mammal. In these methods, an antigen is administered to the mammal with a toxin of a Clostridium (e.g., C. difficile), or a fragment or derivative thereof having adjuvant activity.

Clostridium difficle toxins as mucosal adjuvants

Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.

Multimeric, recombinant urease vaccine

Growing community of inventors

Winchester, MA, United States of America

William D Thomas